The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Self-citationBaigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
Ruggenenti, P., Perna, A., Gherardi, G., Garini, G., Zoccali, C., Salvadori, M., Scolari, F., Schena, F. P., & Remuzzi, G. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10363-x · Cited by 910
Self-citationColhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Livingstone, S. J., Charlton-Menys, V., DeMicco, D. A., & Fuller, J. H. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.03.022 · Cited by 255
Research works printed but not linked: 23
- Gansevoort, 2004, Trends in the incidence of treated end-stage renal failure in The Netherlands: hope for the future?, Kidney Int Suppl, 92, S7, 10.1111/j.1523-1755.2004.09202.x · DOI
- 1997, Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy, Lancet, 349, 1857, 10.1016/S0140-6736(96)11445-8 · DOI · Paper page
- de Zeeuw, 2009, How to improve renal outcome in diabetes and hypertension— the importance of early screening for and treatment of microalbuminuria, Eur Nephrol, 3, 13
- Collins, 2009, United States Renal Data System 2008 Annual Data Report, Am J Kidney Dis, 53, S1
- Campese, 2007, HMG-CoA reductase inhibitors and the kidney, Kidney Int, 71, 1215, 10.1038/sj.ki.5002174 · DOI
- Strippoli, 2008, Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials, BMJ, 336, 645, 10.1136/bmj.39472.580984.AE · DOI · Paper page
- Haynes, 2014, Effects of lowering LDL cholesterol on progression of kidney disease, J Am Soc Nephrol, 25, 1825, 10.1681/ASN.2013090965 · DOI · Paper page
- Levey, 2000, A simplified equation to predict glomerular filtration rate from serum creatinine (abstract), J Am Soc Nephrol, 11, 155A
- Grubb, 2005, Simple cystatin C-based prediction equations for glomerular filtration rate compared with the Modification of Diet in Renal Disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children, Clin Chem, 51, 1420, 10.1373/clinchem.2005.051557 · DOI · Paper page
- Navaneethan, 2009, HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis, Cochrane Database Syst Rev, 15
- Savarese, 2013, Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis, Int J Cardiol, 167, 2482, 10.1016/j.ijcard.2012.05.010 · DOI
- Kose, 2014, Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients, Biol Pharm Bull, 37, 226, 10.1248/bpb.b13-00418 · doi:10.1248/bpb.b13-00418
- DiNicolantonio, 2013, Statin wars: the heavyweight match—atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease, Postgrad Med, 125, 7, 10.3810/pgm.2013.01.2620 · DOI
- Shepherd, 2007, Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study, Clin J Am Soc Nephrol, 2, 1131, 10.2215/CJN.04371206 · DOI · Paper page
- Shepherd, 2004, Safety of rosuvastatin, Am J Cardiol, 94, 882, 10.1016/j.amjcard.2004.06.049 · DOI
- Vidt, 2004, Rosuvastatin-induced arrest in progression of renal disease, Cardiology, 102, 52, 10.1159/000077704 · DOI
- Guthrie, 2007, The safety of rosuvastatin: effects on renal and hepatic function, Expert Opin Drug Saf, 6, 573, 10.1517/14740338.6.5.573 · DOI
- Stein, 2012, Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program, Atherosclerosis, 221, 471, 10.1016/j.atherosclerosis.2011.12.011 · DOI
- Crouse, 2007, Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial, JAMA, 297, 1344, 10.1001/jama.297.12.1344 · DOI · Paper page
- Ridker, 2010, J Am Coll Cardiol, 55, 1266, 10.1016/j.jacc.2010.01.020 · DOI · Paper page
- Guder, 2008, Clinical role of urinary low molecular weight proteins: their diagnostic and prognostic implications, Scand J Clin Lab Invest Suppl, 241, 95, 10.1080/00365510802150174 · DOI
- Sorof, 2006, Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients, Diabetes Res Clin Pract, 72, 81, 10.1016/j.diabres.2005.09.004 · DOI
- Gaspari, 1995, Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate, J Am Soc Nephrol, 6, 257, 10.1681/ASN.V62257 · DOI · Paper page
Cited by
Thomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P.-H., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,230
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
Thomas, M. C., Cooper, M. E., & Zimmet, P. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.173 · Cited by 742
Statin-Associated Side Effects
Thompson, P. D., Panza, G., Zaleski, A., & Taylor, B. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.071 · Cited by 739
Update of pathophysiology and management of diabetic kidney disease
Lin, Y.-C., Chang, Y.-H., Yang, S.-Y., Wu, K.-D., & Chu, T.-S. (2018) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.02.007 · Cited by 562
Signaling pathways of chronic kidney diseases, implications for therapeutics
Yuan, Q., Tang, B., & Zhang, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01036-5 · Cited by 453
Metadata
- Authors
- de Zeeuw, D., Anzalone, D. A., Cain, V. A., Cressman, M. D., Heerspink, H. J. L., Molitoris, B. A., Monyak, J. T., Parving, H.-H., Remuzzi, G., Sowers, J. R., & Vidt, D. G.
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 3
- Issue
- 3
- Pages
- 181-190
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2030853351
- Cited by
- 167
- References
- 6
- FWCI
- 14.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- AstraZeneca
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. https://app.cochat.ai/papers/10.1016/s2213-8587(14)70246-3
- The paper
- de Zeeuw, D., Anzalone, D. A., Cain, V. A., Cressman, M. D., Heerspink, H. J. L., Molitoris, B. A., Monyak, J. T., Parving, H.-H., Remuzzi, G., Sowers, J. R., & Vidt, D. G. (2015). Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(14)70246-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.